Active, not recruitingPhase 2NCT00658814
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Studying Acute erythroid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Sucha Nand, MDSWOG Cancer Research Network
- Intervention
- Azacitidine(drug)
- Enrollment
- 133 enrolled
- Eligibility
- 60 years · All sexes
- Timeline
- 2008 – 2026
Study locations (30)
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
- Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
- Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
- OSF Saint Anthony's Health Center, Alton, Illinois, United States
- Decatur Memorial Hospital, Decatur, Illinois, United States
- Heartland Cancer Research NCORP, Decatur, Illinois, United States
- Advocate Sherman Hospital, Elgin, Illinois, United States
- Loyola University Medical Center, Maywood, Illinois, United States
- SSM Health Good Samaritan, Mount Vernon, Illinois, United States
- Springfield Memorial Hospital, Springfield, Illinois, United States
- Franciscan Saint Francis Health-Beech Grove, Beech Grove, Indiana, United States
- Reid Health, Richmond, Indiana, United States
- Hospital District Sixth of Harper County, Anthony, Kansas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00658814 on ClinicalTrials.gov